Cooley advised Eliem Therapeutics on its $92 million initial public offering of 7,360,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Eliem Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol ELYM, is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Partners Alan Hambelton, Sonya Erickson and Stephen Rosen led the Cooley team.
